HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation

Brain

Volumn 137, Issue 3, 2014, Pages 819-833

  Träger, Ulrike ^a   Andre, Ralph ^a   Lahiri, Nayana ^a   Magnusson Lind, Anna ^a,b   Weiss, Andreas ^c   Grueninger, Stephan ^c   McKinnon, Chris ^a   Sirinathsinghji, Eva ^d   Kahlon, Shira ^e   Pfister, Edith L ^e   Moser, Roger ^f   Hummerich, Holger ^a   Antoniou, Michael ^d   Bates, Gillian P ^d   Luthi Carter, Ruth ^f,g   Lowdell, Mark W ^h   Björkqvist, Maria ^b   Ostroff, Gary R ^e   Aronin, Neil ^e   Tabrizi, Sarah J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c NOVARTIS PHARMA AG   (Switzerland)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f EPFL   (Switzerland)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

gene lowering; Huntington's disease; immunology; myeloid cells

Indexed keywords

CD14 ANTIGEN; GAMMA INTERFERON; GLUCAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUNTINGTIN; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROTEIN FOS; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BONE MARROW CELL; CAG REPEAT; CELL FUNCTION; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRADATION; EXON; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNE RESPONSE; IMMUNOPRECIPITATION; MACROPHAGE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

GENE LOWERING; HUNTINGTON'S DISEASE; IMMUNOLOGY; MYELOID CELLS;

GENE EXPRESSION REGULATION; HUMANS; HUNTINGTON DISEASE; IMMUNITY, INNATE; MYELOID CELLS; NERVE TISSUE PROTEINS; NF-KAPPA B; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; U937 CELLS;

EID: 84894545327     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt355     Document Type: Article

References (63)

1. Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci 2007; 10: 1538-43.
2. Alciato F, Sainaghi PP, Sola D, Castello L, Avanzi GC. TNF-alpha, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/macrophages. J Leukoc Biol 2010; 87: 869-75.
3. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993; 178: 669-74.
4. Anderson AJ, Cummings BJ, Cotman CW. Increased immunoreactivity for Jun-and Fos-related proteins in Alzheimer's disease: association with pathology. Exp Neurol 1994; 125: 286-95.
5. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993; 4: 398-403.
6. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009; 458: 1180-4.
7. Baldo B, Paganetti P, Grueninger S, Marcellin D, Kaltenbach LS, Lo DC, et al. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. Chem Biol 2012; 19: 264-75.
8. Beinke S, Ley SC. Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J 2004; 382 (Pt 2): 393-409.
9. Benn CL, Sun T, Sadri-Vakili G, McFarland KN, DiRocco DP, Yohrling GJ, et al. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci 2008; 28: 10720-33.
10. Bjö rkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 2008 205 1869-77.
11. Bouchard J, Truong J, Bouchard K, Dunkelberger D, Desrayaud S, Moussaoui S, et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci 2012; 32: 18259-68.
12. Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 1997; 60: 1202-10.
13. Brü ck W, Pfö rtner R, Pham T, Zhang J, Hayardeny L, Piryatinsky V, et al Reduced astrocytic NF-kB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol 2012 124 411-24.
14. Colin E, Ré gulier E, Perrin V, Dü rr A, Brice A, Aebischer P, et al. Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci 2005; 21: 1478-88.
15. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366: 1000-9.
16. Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Bjö rkqvist M, Petersén A, et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 2007; 6: 2833-40.
17. DiFiglia M, Sena-Esteves M, Chase K, Sapp E, Pfister E, Sass M, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci USA 2007; 104: 17204-9.
18. Fan J, Gladding CM, Wang L, Zhang LY, Kaufman AM, Milnerwood AJ, et al. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiol Dis 2012; 45: 999-1009.
19. Gauthier LR, Charrin BC, Borrell-Pagè s M, Dompierre JP, Rangone H, Cordeliè res FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004; 118: 127-38.
20. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-64.
21. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998; 16: 111-35.
22. Gross S, Piwnica-Worms D. Real-time imaging of ligand-induced IKK activation in intact cells and in living mice. Nat Methods 2005; 2: 607-14.
23. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368: 117-27.
24. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088-93.
25. Hayden MS, Ghosh S. NF-kB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012; 26: 203-34.
26. Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006; 15: 965-77.
27. Hsiao HY, Chen YC, Chen HM, Tu PH, Chern Y. A critical role of astrocyte-mediated nuclear factor-kB-dependent inflammation in Huntington's disease. Hum Mol Genet 2013; 22: 1826-42.
28. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci USA 1997; 94: 7531-6.
29. Israë l A. The IKK complex: an integrator of all signals that activate NF-kappaB? Trends Cell Biol 2000; 10: 129-33.
30. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 1997; 94: 2642-7.
31. Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, Patterson PH. Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci 2004; 24: 7999-8008.
32. Khoshnan A, Patterson PH. The role of IkB kinase complex in the neurobiology of Huntington's disease. Neurobiol Dis 2011; 43: 305-11.
33. Kwan W, Magnusson A, Chou A, Adame A, Carson MJ, Kohsaka S, et al. Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J Neurosci 2012a; 32: 133-42.
34. Kwan W, Trä ger U, Davalos D, Chou A, Bouchard J, Andre R, et al. Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest 2012b; 122: 4737-47.
35. Lacy P, Stow JL. Cytokine release from innate immune cells: association with diverse membrane trafficking pathways. Blood 2011; 118: 9-18.
36. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-9.
37. Li SH, Schilling G, Young WS, Li XJ, Margolis RL, Stine OC, et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 1993; 11: 985-93.
38. Maguire O, Collins C, O'Loughlin K, Miecznikowski J, Minderman H. Quantifying nuclear p65 as a parameter for NF-kB activation: correlation between ImageStream cytometry, microscopy, and Western blot. Cytometry A 2011; 79: 461-9.
39. Mattson MP, Meffert MK. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ 2006; 13: 852-60.
40. Miyamoto S. Nuclear initiated NF-kB signaling: NEMO and ATM take center stage. Cell Res 2011; 21: 116-30.
41. Munsie L, Caron N, Atwal RS, Marsden I, Wild EJ, Bamburg JR, et al. Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. Hum Mol Genet 2011; 20: 1937-51.
42. Nucifora FC, Sasaki M, Peters MF, Huang H, Cooper JK, Yamada M, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001; 291: 2423-8.
43. O'Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997; 20: 252-8.
44. Perrin V, Dufour N, Raoul C, Hassig R, Brouillet E, Aebischer P, et al. Implication of the JNK pathway in a rat model of Huntington's disease. Exp Neurol 2009; 215: 191-200.
45. Rajesh M, Mukhopadhyay P, Bá tkai S, Haskó G, Liaudet L, Huffman JW, et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 2007; 293: H2210-8.
46. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009; 27: 119-45.
47. Sah DW, Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest 2011; 121: 500-7.
48. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001; 60: 161-72.
49. Simard AR, Rivest S. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. FASEB J 2004; 18: 998-1000.
50. Soulet D, Cicchetti F. The role of immunity in Huntington's disease. Mol Psychiatry 2011; 16: 889-902.
51. Steffan JS. Does Huntingtin play a role in selective macroautophagy? Cell Cycle 2010; 9: 3401-13.
52. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci USA 2000; 97: 6763-8.
53. Sundström C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976; 17: 565-77.
54. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007; 130 (Pt 7): 1759-66.
55. Teng FY, Tang BL. NF-kappaB signaling in neurite growth and neuronal survival. Rev Neurosci 2010; 21: 299-313.
56. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993; 72: 971-83.
57. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol 2009; 187: 1083-99.
58. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed 2006; 8: 25.
59. van der Burg JM, Bjö rkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 2009; 8: 765-74.
60. Weiss A, Trä ger U, Wild EJ, Grueninger S, Farmer R, Landles C, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J Clin Invest 2012; 122: 3731-6.
61. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci USA 2004; 101: 3498-503.
62. Wild E, Magnusson A, Lahiri N, Krus U, Orth M, Tabrizi SJ, et al. Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr 2011; 3: RRN1231.
63. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011; 145: 863-74.